12月22日,，國(guó)際著名雜志Nature刊登了國(guó)外研究人員的最新研究成果“Cancer immunotherapy comes of age,。”文章中，研究者揭示了用于癌癥治療的主動(dòng)免疫療法的最新進(jìn)展,。
利用單克隆抗體和供體T細(xì)胞進(jìn)行的被動(dòng)免疫療法對(duì)某些類型的癌癥是有效的,，但盡管人們進(jìn)行了廣泛研究,，對(duì)特定的,、有耐久性的抗腫瘤免疫實(shí)施主動(dòng)刺激仍然難以實(shí)現(xiàn),。最近,，隨著用于前列腺癌的sipuleucel-T療法和用于一些轉(zhuǎn)移性黑素瘤的ipilimumab藥物的研發(fā)成功，這種情況已經(jīng)得到改變。這些成果使人們對(duì)癌癥免疫療法重新產(chǎn)生了興趣。這篇Review文章總結(jié)了有關(guān)疫苗、T細(xì)胞免疫調(diào)控因子和其他活性免疫刺激藥物的最新研究工作,，這些藥物與定向療法相結(jié)合,，可能會(huì)導(dǎo)致未來(lái)癌癥治療方法的問(wèn)世。（生物谷Bioon.com）
doi:10.1038/nature10673
PMC:
PMID:
Cancer immunotherapy comes of age
Ira Mellman,George Coukos& Glenn Dranoff
Activating the immune system for therapeutic benefit in cancer has long been a goal in immunology and oncology. After decades of disappointment, the tide has finally changed due to the success of recent proof-of-concept clinical trials. Most notable has been the ability of the anti-CTLA4 antibody, ipilimumab, to achieve a significant increase in survival for patients with metastatic melanoma, for which conventional therapies have failed. In the context of advances in the understanding of how tolerance, immunity and immunosuppression regulate antitumour immune responses together with the advent of targeted therapies, these successes suggest that active immunotherapy represents a path to obtain a durable and long-lasting response in cancer patients.
